ANIP - ANI PHARMACEUTICALS INC
IEX Last Trade
55.01
0.430 0.782%
Share volume: 7,120
Last Updated: Thu 26 Dec 2024 08:29:55 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$54.58
0.43
0.79%
Fundamental analysis
28%
Profitability
15%
Dept financing
41%
Liquidity
75%
Performance
27%
Performance
5 Days
-0.09%
1 Month
-6.39%
3 Months
-7.10%
6 Months
-17.30%
1 Year
-2.08%
2 Year
37.29%
Key data
Stock price
$55.01
DAY RANGE
$53.02 - $54.81
52 WEEK RANGE
$54.33 - $70.81
52 WEEK CHANGE
-$1.20
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Nikhil Lalwani
Region: US
Website: anipharmaceuticals.com
Employees: 600
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: anipharmaceuticals.com
Employees: 600
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
ANI Pharmaceuticals, Inc. develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Recent news